Výsledky vyhledávání - "Matthieu Ruffin"

Effect of Hepatic Impairment on the Pharmacokinetics of Pasireotide (SOM230): Results From a Multicenter Phase I Study

Autor: Ke Hu, Douglas M. Heuman, Dago Mazur, Frans-Peter Botha, Matthieu Ruffin, Yanfeng Wang, Dongweon Song, Yves Horsmans, Ying Wang, Emmanuel Bouillaud

Publikováno v: The Journal of Clinical Pharmacology. 52:552-558

Pasireotide is a novel, multireceptor-targeted somatostatin analogue with high affinity for sst(1,2,3) and sst(5) under clinical evaluation in tumors of neuroendocrine origin, including Cushing's disease, acromegaly, and neuroendocrine tumors. In thi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6b0f3bce9d3875019200c0ef9a9dbe5
https://doi.org/10.1177/0091270011400072

Zobrazit plný text záznamu

Safety, tolerability, and pharmacokinetics of a single dose of pasireotide long-acting release in healthy volunteers: a single-center Phase I study

Autor: Hartmut Dietrich, Emmanuel Bouillaud, Ke Hu, Matthieu Ruffin, Yanfeng Wang, Jens Hasskarl, Dongweon Song

Publikováno v: European Journal of Endocrinology. 166:821-828

Objective: This study was conducted to evaluate the safety, tolerability, and pharmacokinetics (PKs) of different doses of a long-acting release (LAR) formulation of pasireotide in healthy subjects. Design: Single-center, open-label, randomized Phase

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a34fd7f6b2163ebee89f22502d0a9e04
https://doi.org/10.1530/eje-11-0773

Zobrazit plný text záznamu

Pasireotide versus octreotide in acromegaly: A head-to-head superiority study

Autor: Mônica R. Gadelha, Matthieu Ruffin, Pamela U. Freda, Annamaria Colao, YinMiao Chen, C. Shen, Andrew J. Farrall, Maria Fleseriu, Marcello D. Bronstein, Michael C. Sheppard, K. Hermosillo Reséndiz, Feng Gu, A. J. van der Lely

Publikováno v: The Journal of Clinical Endocrinology and Metabolism
Journal of Clinical Endocrinology and Metabolism, 99(3), 791-799. Endocrine Society

Context: Biochemical control reduces morbidity and increases life expectancy in patients with acromegaly. With current medical therapies, including the gold standard octreotide long-acting-release (LAR), many patients do not achieve biochemical contr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::519cdd61439b74edfaa40066ebaef7e2
http://hdl.handle.net/11588/617909

Zobrazit plný text záznamu

Erratum to: Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study

Autor: Michael Sheppard, Marcello D. Bronstein, Pamela Freda, Omar Serri, Laura De Marinis, Luciana Naves, Liudmila Rozhinskaya, Karina Hermosillo Reséndiz, Matthieu Ruffin, YinMiao Chen, Annamaria Colao

Publikováno v: Pituitary

A large, randomized, double-blind, Phase III core study demonstrated that pasireotide LAR was significantly superior to octreotide LAR at providing GH2.5 μg/L and normalized IGF-1 after 12 months' treatment in patients with acromegaly. We report the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ec4548bce30695422cd0872be3393ff
https://doi.org/10.1007/s11102-014-0628-z

Zobrazit plný text záznamu

Switching patients with acromegaly from octreotide LAR to pasireotide LAR improves biochemical control: crossover extension to a randomized, double-blind, multicenter, Phase III study

Autor: Annamaria Colao, der Lely Aart Jan van, Marcello D. Bronstein, Pamela U. Freda, Feng Gu, Matthieu Ruffin, Andrew J. Farrall, Chiung-Chyi Shen, Mônica R. Gadelha, Resendiz Karina Hermosillo, Michael C. Sheppard, Maria Fleseriu, YinMiao Chen

Publikováno v: Endocrine Abstracts.

Pasireotide LAR Improves Biochemical Control: Crossover Extension to a Randomized, Double-Blind, Multicenter, Phase III Study P Freda,1 M Fleseriu,2 AJ van der Lely,3 A Colao,4 A Sheppard M,5 F Gu,6 C-C Shen,7 M Gadelha,8 AJ Farrall,9 K Hermosillo Re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a2a8c7550234f740086d04c87b445519
https://doi.org/10.1530/endoabs.32.p847

Zobrazit plný text záznamu

Pasireotide LAR and octreotide LAR maintain inhibition of GH and IGF1 in patients with acromegaly: 12-month extension phase of a randomized, double-blind, multicenter, phase III study

Autor: Luciana Ansaneli Naves, Kobby Asubonteng, Marcello D. Bronstein, Annamaria Colao, Pamela U. Freda, Marinis Laura De, Matthieu Ruffin, Resendiz Karina Hermosillo, Omar Serri, Michael C. Sheppard, Liudmila Rozhinskaya

Publikováno v: Endocrine Abstracts.

in Patients With Acromegaly: 12-Month Extension Phase of a Randomized, Double-Blind, Multicenter, Phase III Study M Sheppard,1 M Bronstein,2 P Freda,3 O Serri,4 L De Marinis,5 L Naves,6 L Rozhinskaya,7 K Hermosillo Resendiz,8 M Ruffin,9 K Asubonteng,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0383841f3fcbc5c1152c9e357d104c4f
https://doi.org/10.1530/endoabs.32.p845

Zobrazit plný text záznamu

Treatment with pasireotide LAR normalizes prolactin levels in patients with acromegaly and hyperprolactinemia: randomized, double-blind, 12-month, phase III study

Autor: Pamela U. Freda, Matthieu Ruffin, Annamaria Colao, Marcello D. Bronstein, Karina Hermosillo Reséndiz, YinMiao Chen, Feng Gu

Publikováno v: Endocrine Abstracts.

A Colao,1 P Freda,2 F Gu,3 K Hermosillo Resendiz,4 M Ruffin,5 Y Chen,4 M Bronstein6 1Dipartimento di Medicina Clinica e Chirurgia, Universita Federico II di Napoli, Naples, Italy; 2Department of Medicine, Columbia University College of Physicians & S

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7cd08d6f6c41381f7e80b8c07ff89c60
https://doi.org/10.1530/endoabs.32.p906

Zobrazit plný text záznamu

Erratum to: Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study

Autor: Matthieu Ruffin, Annamaria Colao, David L. Kleinberg, Karina Hermosillo Reséndiz, Christophe De Block, Andrew J. Farrall, Ariel Barkan, Ross C. Cuneo, Stephan Petersenn, Jochen Schopohl, Ke Hu, Shlomo Melmed, Gareth Hughes, Philippe Caron

Publikováno v: Pituitary

Pasireotide has a broader somatostatin receptor binding profile than other somatostatin analogues. A 16-week, Phase II trial showed that pasireotide may be an effective treatment for acromegaly. An extension to this trial assessed the long-term effic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01118ae3773c94d437b6ecd6185b71c1
https://doi.org/10.1007/s11102-013-0491-3

Zobrazit plný text záznamu

Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study

Autor: Matthieu Ruffin, Mônica R. Gadelha, Pamela U. Freda, Michael C. Sheppard, Sebastian J C M M Neggers, Chiung Chyi Shen, Maria Fleseriu, Feng Gu, Annamaria Colao, Marcello D. Bronstein, Yin Miao Chen, Andrew J. Farrall, Karina Hermosillo Reséndiz

Publikováno v: Bronstein, M D, Fleseriu, M, Neggers, S, Colao, A, Sheppard, M, Gu, F, Shen, C-C, Gadelha, M, Farrall, A J, Hermosillo Reséndiz, K, Ruffin, M, Chen, Y, Freda, P 2016, ' Switching patients with acromegaly from octreotide to pasireotide improves biochemical control : crossover extension to a randomized, double-blind, Phase III study ', BMC Endocrine Disorders, vol. 16, pp. 16 . https://doi.org/10.1186/s12902-016-0096-8
BMC Endocrine Disorders
BMC Endocrine Disorders, 16:16. BioMed Central Ltd.

Background Many patients with acromegaly do not achieve biochemical control with first-generation somatostatin analogues. A large, multicenter, randomized, Phase III core study demonstrated that pasireotide LAR had significantly superior efficacy ove

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0271a1db4da5b834eeed9ff779051a9

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání